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Purpose: Acute clinical events resulting from atherosclerosis (myocardial infarction, stroke) are associated with impaired
endogenous fibrinolysis, the system by which the body lyses inappropriately formed thrombus. Endurance exercise
training improves fibrinolysis in normal subjects and those with coronary artery disease. The hypothesis of this study was
that exercise training would improve fibrinolysis in subjects with peripheral arterial disease (PAD).
Methods and results: Twenty-one men with intermittent claudication (IC-EX) underwent treadmill exercise training for 6
months. Twenty age-matched male subjects with IC were followed for the same period (IC-NONEX). Fibrinolytic
activity was measured prior to entry into exercise or “usual care,” and at the completion of the study period. Fibrinolysis
was quantified by measurement of the activity levels of tissue plasminogen activator (tPA, the activator of fibrinolysis) and
its inhibitor plasminogen activator inhibitor-1 (PAI-1), using an amidolytic method. Fibrinolysis, quantified as increased
PAI-1 activity, was reduced in both claudicant groups relative to healthy controls at baseline. After 6 months of exercise,
subjects in the IC-EX group experienced significant improvements in fibrinolytic activity, manifested as a 23% decrease in
PAI-1 activity and a 28% increase in tPA activity. No changes occurred in the IC-NONEX group. In the IC-EX group,
subjects with the highest initial PAI-1 values experienced the greatest decreases in PAI-1 activity and thus the greatest
benefit from exercise.
Conclusions: Patients with PAD have impaired fibrinolytic activity, manifested primarily as increases in the inhibitor of
fibrinolysis, PAI-1. Six months of exercise training reduced these impairments, and may serve as an intervention to reduce
cardiovascular mortality and morbidity in these patients. ( J Vasc Surg 2004;40:741-5.)There is increasing evidence that acute clinical events
associated with atherosclerosis, such as myocardial infarc-
tion, sudden cardiac death, and stroke, occur when throm-
bus forms on pre-existing atherosclerotic plaque.1,2 Pro-
gression of atherosclerosis is also associated with thrombus
formation, which leads to intimal smooth muscle prolifer-
ation, increased plaque size, and vessel occlusion.3 Both
acute events and progression of disease are associated with
reduced endogenous fibrinolysis, the system by which the
body lyses excess or inappropriately formed thrombus.4-8
Fibrinolysis is regulated by the activity of the serine
protease, tissue plasminogen activator (tPA), and its inhib-
itor plasminogen activator inhibitor-1 (PAI-1). Tissue plas-
minogen activator cleaves the inactive zymogen plasmino-
gen to its active form plasmin, which lyses fibrin clots. It is
inactivated by formation of a 1-to-1 stoichiometric com-
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active.9
Plasminogen activator inhibitor-1 activity is elevated in
patients with coronary artery disease, myocardial infarction,
and stroke.2,4,10,11 In a seemingly paradoxical fashion, total
protein, or antigen, levels of tPA are also elevated. This
occurs because measurement of tPA antigen includes both
free tPA and tPA/PAI-1 complexes, which far exceed the
amount of free tPA. 12 Elevated tPA antigen levels there-
fore represent a hypercoagulable, rather than fibrinolytic,
state.12 In addition, tPA activity is often reduced in these
subjects.2,11
Less is known about endogenous fibrinolysis in patients
with peripheral arterial disease (PAD). However, we13,14
and others have15,16 shown increased PAI-1 activity levels
and, in some cases, increased tPA antigen levels in these
patients.
Endurance exercise training increases fibrinolytic activ-
ity in normal subjects17,18 and those with coronary artery
disease.18 The hypothesis of this study was that exercise
training would improve fibrinolysis in patients with PAD. It
is our hope that, ultimately, exercise training, by increasing
fibrinolysis and decreasing thrombus formation in athero-
sclerotic vessels, will prove to be an intervention to reduce
cardiovascular morbidity and mortality.
METHODS
Twenty-one men with intermittent claudication under-
went treadmill exercise training 3 times a week for 6
months (IC-EX group). The men were consecutive sub-
jects enrolled in a larger study addressing the benefits of
exercise in the treatment of PAD.19 Intermittent claudica-741
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gether with a resting ankle-brachial index (ABI) in the
affected leg 0.90. ABI was determined by measurement
of continuous-wave Doppler-derived ankle and brachial
systolic pressures. All patients underwent a standard graded
treadmill test20 to determine suitability for exercise and
times to onset of claudication pain. Patients who experi-
enced chest pain or significant electrocardiographic evi-
dence of myocardial ischemia during the treadmill test were
excluded from the exercise program.
The exercise protocol consisted of supervised, intermit-
tent treadmill walking to near maximal claudication pain 3
times per week. Intensity and duration increased through-
out the 6-month intervention period. For the first month,
patients walked 15 minutes per session; this was increased
by 5 minutes per month until a duration of 40 minutes was
reached. Intensity was set at grades of 50% to 80% of
maximal work load and adjusted by individual. During each
session, patients walked at approximately 2 miles per hour
until claudication pain reached near maximal; they rested
until the pain resolved and then began again. The pattern of
walking and resting was continued until the prescribed
duration of minutes was reached. Warm-up and cool-down
periods consisted of 5 minutes of stationary cycling. The
program was supervised by a nurse trained in cardiopulmo-
nary resuscitation; no cardiovascular events occurred in any
patient during the training sessions.
The IC-EX group was compared with a group of 20
claudicants who were followed for the 6-month period
without intervention (IC-NONEX). The IC-NONEX
group consisted of consecutive subjects in the same larger
study as the IC-EX group who were not deemed suitable
for exercise training because of the occurrence of chest pain
or electrocardiographic evidence of symptomatic coronary
artery disease during treadmill testing. These patients also
underwent baseline measurements of ABI and walking
times. Both groups underwent measurements of ABI and
walking times at the completion of the 6-month period.
Twelve age- and sex-matched healthy volunteer subjects,
selected from the volunteer registry at the Geriatric Re-
search, Education, and Clinical Center at the Baltimore
Veterans Affairs Medical Center, without evidence of dia-
betes mellitus, coronary artery disease, hypertension, hy-
perlipidemia, or PAD served as a control group (HS-CTL).
Study participants underwent antecubital venipuncture
for quantification of fibrinolytic activity 5 to 7 days prior to
initiation of exercise or usual care, and 5 to 7 days after
completion. Fibrinolysis was quantified by measurements
of the biologic activities of tPA and PAI-1. Samples were
collected without tourniquet-induced venostasis at the
same time of day to eliminate the known diurnal variations
in tPA and PAI-1.21 For determination of tPA activity,
blood was first collected into 130 mmol/L sodium citrate
anticoagulant (9:1 volume) and immediately acidified by
addition of 0.5 mmol/L sodium acetate, pH 4.2 (2:1
volume), to prevent the ongoing in vitro inactivation of
tPA by complex formation with PAI-1.22 Samples for mea-
surement of PAI-1 activity were collected into a 5-mLsyringe containing modified Files solution (1-mL acid ci-
trate dextrose solution, 80-L acetylsalicylic acid solution,
10-L prostaglandin E1) to minimize in vitro platelet
activation (final dilution 1:5).23 Samples were maintained
at 4°C until centrifugation at 10,000  g for 20 minutes.
Platelet-poor plasma was stored at -80°C until assays were
performed.
The activity levels of tPA and PAI-1 were measured by
using an amidolytic method.24 All assays were performed in
duplicate, and interassay variability was determined to be
5%. Tissue plasminogen activator activity was expressed
in international units (IU/mL) assessed against the second
International Standard for tPA from the National Institute
for Biological Standards and Control.25 PAI-1 activity was
expressed in arbitrary units (AU/mL); 1 arbitrary unit of
inhibitor is defined as the amount which inhibits 1 IU of
tPA/mL plasma.26
Values for tPA and PAI-1 activity were combined for all
subjects in each group pre- and post-intervention or usual
care. Values were expressed as mean SEM. Changes over
time within the same group and among groups at the same
time interval were determined by using a repeated measures
analysis of variance. The relationship between changes in
PAI-1 activity with exercise and baseline values in the
IC-EX group was determined by using linear regression
analysis. Differences in the prevalence of risk factors for
atherosclerosis were determined using the Fisher exact test.
A P value of .05 was considered statistically significant.
This protocol was approved by the Institutional Review
Board of the University of Maryland, and all subjects gave
informed consent prior to participation. Procedures fol-
lowed were in accordance with guidelines of the University
of Maryland and the Baltimore Veterans Affairs Medical
Center.
RESULTS
Patient demographics. Table I lists the prevalence of
risk factors for PAD in the 2 groups of patients with
Table I. Patient demographics
IC-EX IC-NONEX
n % n %
Age (y)* 68  1 70 2
Race†
Caucasian 14 67 16 80
African American 7 33 4 20
Tobacco use†
Never 3 14 4 20
Former 13 62 9 45
Current 5 24 7 35
Hypertension† 15 71 18 90
Hyperlipidemia† 9 43 10 50
Diabetes mellitus† 14 67 14 70
*P  .05, Student t test.
†P  .05, Fisher exact test for prevalence of all characteristics between
exercising intermittent claudication and nonexercising intermittent claudi-
cation groups.
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the groups (P  .05) in the prevalence of diabetes mellitus
(defined by the use of insulin or a hypoglycemic medica-
tion), hypertension, hyperlipidemia (defined as the use of a
lipid-lowering agent), or tobacco usage. Both groups con-
tained equivalent proportions of Caucasians and African
Americans. All study participants were male, and the 2
groups were of similar ages.
ABI and walking times. Baseline, pre-intervention
ABIs were similar in the IC-EX and IC-NONEX groups
(0.61  0.04 and 0.56  0.06, respectively, P  .05) but
significantly lower than in the healthy control group (ABI,
1.21; P .004). Neither group of claudicants experienced
a significant change in ABI over the 6-month period of
exercise training or usual care (6-month IC-EX  0.61 
0.01, P 0.94 vs baseline; 6-month IC-NONEX 0.60
0.02, P  0.82 vs baseline). The IC-EX group did achieve
improved walking ability, however, as evidenced by signif-
icant increases in the time to onset of claudication pain (P
.001) and the maximal walking time (P  .002). No
changes in walking times occurred in the IC-NONEX
group (P  .05; Table II).
Table II. Walking times (s) at baseline and after 6
months of exercise or usual care
IC-EX IC-NONEX
Time to onset IC (s)
Baseline 190  33* 175 40
6 mo 413  77* 204 64
Max walking time (s)
Baseline 443  60† 410  36
6 mo 752  73† 426  53
P values in the nonexercising intermittent claudication group  0.05
baseline vs 6 mo.
*P  .001.
†P  .002.
Table III. tPA activity (IU/mL, mean  SEM) at
baseline and after 6 months of exercise or usual care
Baseline P* 6 mo P†
HS-CTL 1.74 0.25
IC-NONEX 1.48  0.31 .077 1.43  0.28 .55
IC-EX 1.47  0.19 .068 1.88  0.20 .003
*Intermittent claudication (IC) group vs controls at baseline.
†IC group baseline vs 6 months.
Table IV. PAI-1 activity (AU/mL, mean  SEM) at
baseline and after 6 months of exercise or usual care
Baseline P* 6 mo P†
HS-CTL 12.4 1.7
IC-NONEX 18.9  1.9 .009 18.6  1.6 .79
IC-EX 22.3 1.8 .005 18.0  1.1 .001
*P value for intermittent claudication (IC) group vs controls at baseline.
†P value for IC group baseline vs 6 mo.Tissue plasminogen activator activity. Tissue plas-
minogen activator activity was lower at baseline in the 2
claudicant groups than in the healthy control subjects,
although these values did not attain statistical significance
(Table III). After 6 months of exercise training, the tPA
activity level in the IC-EX group increased 28% (P  .003,
Table II). No change occurred in the IC-NONEX group
after 6 months of usual care (P  .55, Table III).
Plasminogen activator inhibitor-1 activity. PAI-1
activity was significantly elevated in the 2 groups of claudi-
cants relative to the healthy control subjects before inter-
vention (Table IV). After 6 months of exercise training,
PAI-1 activity decreased by 23% in the IC-EX group (P 
.001, Table III). No change in PAI-1 activity was observed
in the IC-NONEX group after 6 months of usual care
(Table IV).
The change in PAI-1 activity after 6 months of exercise
training was related to the baseline value for each patient in
the IC-EX group (Fig). Patients with the highest pre-
intervention PAI-1 activity levels experienced the greatest
benefit from exercise training, manifested by the largest
decreases in PAI-1 activity. Those patients with the lowest,
or most normal, PAI-1 activity levels experienced the least
benefit from exercise training, manifested by the smallest
decreases in PAI-1 activity (r  -0.70, P  .001).
DISCUSSION
Numerous studies have demonstrated that impair-
ments of the endogenous fibrinolytic system are present in
patients with coronary artery disease, and these impair-
ments may be associated with an increased risk of clinical
events such as myocardial infarction, sudden cardiac death,
and stroke.2,4,10-12 We and others have demonstrated that
impaired fibrinolysis also occurs in patients with PAD,
including those with intermittent claudication as well as
Change in PAI-1 activity after exercise training for each subject in
IC-EX group compared with baseline values.
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previously showed that more severe claudication was asso-
ciated with greater reductions of fibrinolysis than mild
claudication.14 In these studies, reduced fibrinolysis was
manifested as elevations in PAI-1 activity and tPA antigen
and decreases in tPA activity.14 In the study reported here,
we also found that fibrinolysis was impaired in claudicants,
primarily manifested as increases in PAI-1 activity.
Endurance exercise training enhances fibrinolysis in
healthy adult subjects17,18,28 as well as those with coronary
artery disease,29,30 impaired glucose tolerance,31 and dia-
betes mellitus.32 Few studies have addressed the benefits of
exercise on abnormalities of fibrinolysis in patients with
PAD. It has been speculated that reduced exercise capacity
(due to intermittent claudication) in patients with PAD
would limit the degree to which they could achieve in-
creased fibrinolysis through exercise. However, Womack et
al33 demonstrated that even an acute bout of exercise
improves fibrinolysis in these subjects. In a previous study,
we demonstrated that PAD subjects with higher daily phys-
ical activity levels had increased fibrinolytic activity com-
pared with those with lower daily physical activity levels.34
To ensure that the measurements performed in this study
reflected the effect of endurance training, rather than a
single bout, we performed blood sampling for quantifica-
tion of fibrinolytic activity 5 to 7 days after completion of
the exercise protocol. During this period, all subjects were
instructed to perform normal activities of daily living, but
not to undertake any planned exercise.
Tissue plasminogen activator activity increased 28%
after exercise training in this study, while PAI-1 activity
decreased 23%. Compared with age- and sex-matched con-
trols, tPA activity after exercise training was normalized.
Plasminogen activator inhibitor-1 activity, however, re-
mained elevated.35 Although a definitive explanation for
these findings is not possible, it may be related to the
presence of other diseases in our study population such as
diabetes mellitus, which increase PAI-1 levels but have no
effect on tPA.31
An important finding in this study was that patients
who benefited the most from exercise, in terms of reduced
PAI-1 activity, were those who entered the protocol with
the highest levels. Patients with the most normal PAI-1
activity levels derived the least benefit from exercise, in
terms of reduced PAI-1. The differences in baseline PAI-1
activities as well as the differential effects of exercise may be
related to the 4G/5G polymorphism of the PAI-1 gene.
The 4G/4G polymorphism has been associated with
higher baseline PAI-1 activity and a greater response to
exercise.36
One weakness of this study is the lack of randomization
of subjects. Although we initially intended to randomize
subjects to exercise or usual care, by far the majority of
subjects who volunteered were classified as unsuitable for
exercise on the basis of comorbidities, primarily symptom-
atic coronary artery disease. Ultimately, we elected to
forego randomization in favor of more rapid subject ac-
crual. Since the “healthier” subjects underwent exercise, itis possible that this factor alone may have influenced the
responsiveness of their fibrinolytic activity to exercise.
Moreover, the baseline PAI-1 activity levels in the IC-EX
group were higher than in the IC-NONEX group. It is
possible that these higher baseline values affected the re-
duction in PAI-1 activity with exercise, since the regression
analysis showed that subjects with higher values had a
greater response. A larger, randomized study will be neces-
sary to provide definitive answers to these issues.
It is well documented that exercise reduces cardiovas-
cular morbidity and mortality in patients with coronary
artery disease. In the Honolulu Heart Study, older men
who walked more than 2 miles per day had a significantly
reduced risk of myocardial infarction or cardiovascular
death compared with men who walked less than 1 mile per
day.37 Numerous other studies have confirmed this ef-
fect.38 It is possible that subjects who exercise regularly
reduce their risk of myocardial infarction and cardiovascular
death in part by reduced thrombus formation in atheroscle-
rotic vessels mediated through higher fibrinolytic activity.
In this study, we found that exercise improved fibrinolysis
in subjects with intermittent claudication, and therefore
may serve as an intervention strategy to reduce cardiovas-
cular complications and retard progression of disease in this
population.
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